Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Cell Death & Disease|October 21, 2020
EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewalRoberto Paredes, James R Kelly, Bethany Geary, et al.Cell Reports|January 23, 2026
Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemiaLiam Clayfield, Divya Malik, Jessica Whittle, et al.Cancer Cell|November 23, 2023
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesLuciano Nicosia, Gary J Spencer, Nigel Brooks, et al.Nucleic Acids Research|June 26, 2018
EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 associationRoberto Paredes, Marion Schneider, Adam Stevens, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.Cancer Cell|April 25, 2025
Stromal lipid species dictate melanoma metastasis and tropismShilpa Gurung, Timothy Budden, Karthik Mallela, et al.Journal of Medicinal Chemistry|December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia CellsStuart Jones, Jonathan Ahmet, Kelly Ayton, et al.Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.Cell Stem Cell|April 30, 2019
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid LeukemiaJasmin Paris, Marcos Morgan, Joana Campos, et al.Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.Pageof 8